Drug intelligence / Profile preview

TRPV3 inhibitor (Salipro Biotech)

Development stage
Preclinical
Lead developer
Salipro Biotech
Modality
Small Molecules
01

Overview

TRPV3 inhibitor (Salipro Biotech) is a preclinical-stage therapeutic candidate being developed by Salipro Biotech for the treatment of CNS-related pain. The program targets the Transient Receptor Potential Vanilloid 3 (TRPV3) ion channel, a calcium-permeable non-selective cation channel involved in thermosensation and nociception. Salipro Biotech utilizes its proprietary Salipro® technology to stabilize the multi-pass transmembrane TRPV3 protein in a native-like lipid environment, which facilitates the discovery and development of potent and selective modulators. By inhibiting TRPV3 activity in the central nervous system, the drug aims to provide a novel analgesic approach for managing chronic pain conditions.

Other names
Salipro Biotech TRPV3 program
02

Targets

TRPV3 (Transient receptor potential vanilloid subtype 3)

Beyond the preview

Go deeper on TRPV3 inhibitor (Salipro Biotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRPV3 inhibitor (Salipro Biotech).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call